Skip to main content

Altered Expression of Proteins in Cancer: Function and Potential Therapeutic Targets, Volume II

104kviews
Editorial: Altered expression of proteins in cancer: function and potential therapeutic targets, volume II
Editorial18 July 2023
Editorial: Altered expression of proteins in cancer: function and potential therapeutic targets, volume II

Cancer cells and cells of the tumor microenvironment (TME) show extensive biochemical alterations, which provide multiple opportunities for developing innovative strategies for diagnosis, therapy, and prognosis. The disrupted metabolism of cancer cells (1) and immune cells of the TME (2) is controlled by several protein families. As such, it is not surprising that many of them have their cellular levels significantly increased or decreased. In the first volume of the Research Topic "Altered Expression of Proteins in Cancer: Function and Potential Therapeutic Targets", we provided an update on proteins whose cellular levels are altered in cancer, highlighting their promise for diagnosis and therapy.The second volume of this Research Topic complements the first one. It contains 9 original research articles and 5 review articles. In the following sections, we summarize the main concepts and findings of these studies, grouped according to the main physiological or pathological role of each protein.

Proteins with altered cellular levels in cancer cells include those regulating gene These studies exemplify the multiple direct and indirect players involved in gene expression and their complex regulation, whose disruption in cancer cells affects the levels of messenger RNA (mRNA) and translated proteins.

Cellular levels of functional proteins are also determined by the equilibrium between their phosphorylation and degradation. These processes, also governed by proteins, can be disrupted in cancer cells. Pidkovka and Belkhiri reviewed the impact of the up-regulated transmembrane AXL receptor tyrosine kinase in gastrointestinal cancers and its potential role as a therapeutic target. Inhibition of this protein with small molecules or antibodies is currently being investigated in several clinical trials. In addition, Tang et al. reviewed the relevance of intracellular non-receptor protein tyrosine phosphatases across multiple cancer histologies. Some of these proteins seem to play a dual role in specific cancer types. They are also emerging as targets for immunotherapy and specific These studies introduce novel strategies to interfere with cell division or to induce apoptosis, which provide promising outcomes against uncontrolled proliferation, the most distinctive feature of cancer cells.

The effects of altered protein levels can reach beyond their cell of origin. Through These studies demonstrate that proteins related to the propagation of cancer features are promising tools for diagnosis and prognosis.

The data reported in the present Research Topic provide novel data about regulatory proteins expressed in cancer cells and in immune cells of the TME.These regulatory proteins can control not only primary tumor growth and metastasis but also the efficiency of anti-cancer therapies. These proteins include transcription factors, which affect the levels of transcribed mRNA and translated protein. They also include enzymes involved in protein phosphorylation, dephosphorylation, and degradation, whose altered expression deregulates the levels of functional proteins (Figure 1A). These alterations can affect processes including cell division and apoptosis (Figure 1B). Altered protein levels can exert effects on a larger scale, by modifying the TME and promoting tumor angiogenesis (Figure 1C).

2,223 views

1 citations

ORIGINAL RESEARCH
14 March 2023
Comprehensive analysis of the FOXA1-related ceRNA network and identification of the MAGI2-AS3/DUSP2 axis as a prognostic biomarker in prostate cancer
Guo Yang, 10 more and Yongbo Zheng

3,264 views

9 citations

ORIGINAL RESEARCH
21 February 2023
Angiogenesis regulators S100A4, SPARC and SPP1 correlate with macrophage infiltration and are prognostic biomarkers in colon and rectal cancers
Elena Kazakova, 10 more and Irina Larionova
Angiogenesis regulators S100A4, SPARC and SPP1 correlate with macrophage infiltration and are prognostic biomarkers in colon and rectal cancers
Increasing evidence suggests that it is necessary to find effective and robust clinically validated prognostic biomarkers that can identify "high-risk" colorectal cancer (CRC) patients. Currently, available prognostic factors largely include clinical-pathological parameters and focus on the cancer stage at the time of diagnosis. Among cells of the tumor microenvironment (TME) only Immunoscore classifier based on T lymphocytes showed high predictive value. In the present study, we performed the complex analysis of mRNA and protein expression of crucial regulators of tumor angiogenesis and tumor progression, expressed by tumor-associated macrophages (TAMs): S100A4, SPP1 and SPARC. Colon and rectal cancer patients were investigated independently and in a combined cohort (CRC). For mRNA expression, we analyzed RNA sequencing data obtained from TCGA (N=417) and GEO (N=92) cohorts of colorectal cancer patients. For protein expression, we performed IHC digital quantification of tumor tissues obtained from 197 patients with CRC treated in the Department of abdominal oncology in Clinics of Tomsk NRMC. Notably, high S100A4 mRNA expression accurately predicts poor survival for patients with CRC independently of cancer type. SPARC mRNA level is independent prognostic factors for survival in colon but not in rectal cancer. SPP1 mRNA level is found to have significant predictive value for survival in both rectal and colon cancers. Analysis of human CRC tissues revealed that S100A4, SPP1 and SPARC are expressed by stromal compartments, in particular by TAMs, and have a strong correlation with macrophage infiltration. Finally, our results indicate that chemotherapy-based treatment can change the predictive direction of S100A4 for rectal cancer patients. We found that S100A4 stromal levels were higher in patients with better response to neoadjuvant chemotherapy/chemoradiotherapy, and S100A4 mRNA levels predicted better DFS among non-responders.

7,242 views

50 citations

Bidirectional nucleo-cytoplasmic transport, regulating several vital cellular processes, is mediated by the Nuclear Pore Complex (NPC) comprising the nucleoporin (Nup) proteins. Nup88, a constituent nucleoporin, is overexpressed in many cancers, and a positive correlation exists between progressive stages of cancer and Nup88 levels. While a significant link of Nup88 overexpression in head and neck cancer exists but mechanistic details of Nup88 roles in tumorigenesis are sparse. Here, we report that Nup88 and Nup62 levels are significantly elevated in head and neck cancer patient samples and cell lines. We demonstrate that the elevated levels of Nup88 or Nup62 impart proliferation and migration advantages to cells. Interestingly, Nup88-Nup62 engage in a strong interaction independent of Nup-glycosylation status and cell-cycle stages. We report that the interaction with Nup62 stabilizes Nup88 by inhibiting the proteasome-mediated degradation of overexpressed Nup88. Overexpressed Nup88 stabilized by interaction with Nup62 can interact with NF-κB (p65) and sequesters p65 partly into nucleus of unstimulated cells. NF-κB targets like Akt, c-myc, IL-6 and BIRC3 promoting proliferation and growth are induced under Nup88 overexpression conditions. Our data indicates that simultaneous overexpression of Nup62 and Nup88 in head and neck cancer stabilizes Nup88. Stabilized Nup88 interacts and activates p65 pathway, which perhaps is the underlying mechanism in Nup88 overexpressing tumors.

6,363 views

22 citations

ORIGINAL RESEARCH
16 February 2023
USP20 is a predictor of poor prognosis in colorectal cancer and associated with lymph node metastasis, immune infiltration and chemotherapy resistance
RuiRi Jin, 7 more and YouXiang Chen

4,928 views

13 citations

Notch signaling, hypoxia, and cancer
Notch signaling is involved in cell fate determination and deregulated in human solid tumors. Hypoxia is an important feature in many solid tumors, which activates hypoxia-induced factors (HIFs) and their downstream targets to promote tumorigenesis and cancer development. Recently, HIFs have been shown to trigger the Notch signaling pathway in a variety of organisms and tissues. In this review, we focus on the pro- and anti-tumorigenic functions of Notch signaling and discuss the crosstalk between Notch signaling and cellular hypoxic response in cancer pathogenesis, including epithelia-mesenchymal-transition, angiogenesis, and the maintenance of cancer stem cells. The pharmacological strategies targeting Notch signaling and hypoxia in cancer are also discussed in this review.

6,806 views

52 citations

ORIGINAL RESEARCH
6 January 2023
Quantitative tissue proteome profile reveals neutrophil degranulation and remodeling of extracellular matrix proteins in early stage gallbladder cancer
Javed Akhtar, 10 more and Poonam Gautam

3,906 views

17 citations

Tripartite motif (TRIM) 31 is a new member of the TRIM family and functions as an E3 ubiquitin ligase. Abnormal TRIM31 expression leads to a variety of pathological conditions, such as cancer, innate immunity diseases, sepsis-induced myocardial dysfunction, cerebral ischemic injury, nonalcoholic fatty liver disease and hypertensive nephropathy. In this review, we comprehensively overview the structure, expression and regulation of TRIM31 in cancer. Moreover, we discuss the dual role of TRIM31 in human cancer, and this dual role may be linked to its involvement in the selective regulation of several pivotal cellular signaling pathways: the p53 tumor suppressor, mTORC1, PI3K-AKT, NF-κB and Wnt/β-catenin pathways. In addition, we also discuss the emerging role of TRIM31 in innate immunity, autophagy and its growing sphere of influence across multiple human pathologies. Finally, a better understanding of the dual role of TRIM31 in cancer may provide new therapeutic strategies aimed at inhibiting the cancer-promoting effects of TRIM31 without affecting its tumor suppressor effects.

6,054 views

24 citations

ORIGINAL RESEARCH
21 December 2022
NUF2 overexpression contributes to epithelial ovarian cancer progression via ERBB3-mediated PI3K-AKT and MAPK signaling axes
Ruobing Leng, 2 more and Yingzi Zhao

3,323 views

23 citations

REVIEW
20 October 2022
Tumor microenvironment and exosomes in brain metastasis: Molecular mechanisms and clinical application
Yirizhati Aili, 5 more and Yongxin Wang

4,930 views

15 citations

Since tyrosine phosphorylation is reversible and dynamic in vivo, the phosphorylation state of proteins is controlled by the opposing roles of protein tyrosine kinases (PTKs) and protein tyrosine phosphatase (PTPs), both of which perform critical roles in signal transduction. Of these, intracellular non-receptor PTPs (PTPNs), which belong to the largest class I cysteine PTP family, are essential for the regulation of a variety of biological processes, including hematopoiesis, inflammatory response, immune system, and glucose homeostasis. Additionally, a substantial amount of PTPNs have been identified to hold crucial roles in tumorigenesis, progression, metastasis, and drug resistance, and inhibitors of PTPNs have promising applications due to striking efficacy in antitumor therapy. Hence, the aim of this review is to summarize the role played by PTPNs, including PTPN1/PTP1B, PTPN2/TC-PTP, PTPN3/PTP-H1, PTPN4/PTPMEG, PTPN6/SHP-1, PTPN9/PTPMEG2, PTPN11/SHP-2, PTPN12/ PTP-PEST, PTPN13/PTPL1, PTPN14/PEZ, PTPN18/PTP-HSCF, PTPN22/LYP, and PTPN23/HD-PTP, in human cancer and immunotherapy and to comprehensively describe the molecular pathways in which they are implicated. Given the specific roles of PTPNs, identifying potential regulators of PTPNs is significant for understanding the mechanisms of antitumor therapy. Consequently, this work also provides a review on the role of non-coding RNAs (ncRNAs) in regulating PTPNs in tumorigenesis and progression, which may help us to find effective therapeutic agents for tumor therapy.

11,306 views

39 citations